- Home
- ACRS vs TCX Comparison
ACRS vs TCX Comparison
Compare ACRS & TCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- TCX
- Stock Information
- Founded
- ACRS 2012
- TCX 1992
- Country
- ACRS United States
- TCX Canada
- Employees
- ACRS N/A
- TCX N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- TCX EDP Services
- Sector
- ACRS Health Care
- TCX Technology
- Exchange
- ACRS Nasdaq
- TCX Nasdaq
- Market Cap
- ACRS 230.8M
- TCX 233.3M
- IPO Year
- ACRS 2015
- TCX 1996
- Fundamental
- Price
- ACRS $2.85
- TCX $21.68
- Analyst Decision
- ACRS Strong Buy
- TCX
- Analyst Count
- ACRS 5
- TCX 0
- Target Price
- ACRS $9.75
- TCX N/A
- AVG Volume (30 Days)
- ACRS 1.4M
- TCX 30.4K
- Earning Date
- ACRS 11-06-2025
- TCX 11-06-2025
- Dividend Yield
- ACRS N/A
- TCX N/A
- EPS Growth
- ACRS N/A
- TCX N/A
- EPS
- ACRS N/A
- TCX N/A
- Revenue
- ACRS $15,742,000.00
- TCX $384,728,000.00
- Revenue This Year
- ACRS N/A
- TCX N/A
- Revenue Next Year
- ACRS N/A
- TCX N/A
- P/E Ratio
- ACRS N/A
- TCX N/A
- Revenue Growth
- ACRS N/A
- TCX 8.03
- 52 Week Low
- ACRS $1.05
- TCX $13.27
- 52 Week High
- ACRS $4.24
- TCX $23.38
- Technical
- Relative Strength Index (RSI)
- ACRS 67.71
- TCX 59.17
- Support Level
- ACRS $2.34
- TCX $19.85
- Resistance Level
- ACRS $2.57
- TCX $22.63
- Average True Range (ATR)
- ACRS 0.22
- TCX 1.16
- MACD
- ACRS 0.03
- TCX 0.07
- Stochastic Oscillator
- ACRS 96.18
- TCX 63.51
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About TCX Tucows Inc.
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. Geographically company operates in USA, Canada and Europe.